Aarti Pharmalabs appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Subscribe To Our Newsletter & Stay Updated